Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2014 2
2015 9
2016 4
2017 3
2018 5
2019 2
2020 4
2021 12
2022 8
2023 3
2024 4
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy.
Rehman SK, Haynes J, Collignon E, Brown KR, Wang Y, Nixon AML, Bruce JP, Wintersinger JA, Singh Mer A, Lo EBL, Leung C, Lima-Fernandes E, Pedley NM, Soares F, McGibbon S, He HH, Pollet A, Pugh TJ, Haibe-Kains B, Morris Q, Ramalho-Santos M, Goyal S, Moffat J, O'Brien CA. Rehman SK, et al. Among authors: bruce jp. Cell. 2021 Jan 7;184(1):226-242.e21. doi: 10.1016/j.cell.2020.11.018. Cell. 2021. PMID: 33417860 Free PMC article.
Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape.
Bruce JP, To KF, Lui VWY, Chung GTY, Chan YY, Tsang CM, Yip KY, Ma BBY, Woo JKS, Hui EP, Mak MKF, Lee SD, Chow C, Velapasamy S, Or YYY, Siu PK, El Ghamrasni S, Prokopec S, Wu M, Kwan JSH, Liu Y, Chan JYK, van Hasselt CA, Young LS, Dawson CW, Paterson IC, Yap LF, Tsao SW, Liu FF, Chan ATC, Pugh TJ, Lo KW. Bruce JP, et al. Nat Commun. 2021 Jul 7;12(1):4193. doi: 10.1038/s41467-021-24348-6. Nat Commun. 2021. PMID: 34234122 Free PMC article.
FAM72A degrades UNG2 through the GID/CTLH complex to promote mutagenic repair during antibody maturation.
Barbulescu P, Chana CK, Wong MK, Ben Makhlouf I, Bruce JP, Feng Y, Keszei AFA, Wong C, Mohamad-Ramshan R, McGary LC, Kashem MA, Ceccarelli DF, Orlicky S, Fang Y, Kuang H, Mazhab-Jafari M, Pezo RC, Bhagwat AS, Pugh TJ, Gingras AC, Sicheri F, Martin A. Barbulescu P, et al. Among authors: bruce jp. Nat Commun. 2024 Aug 30;15(1):7541. doi: 10.1038/s41467-024-52009-x. Nat Commun. 2024. PMID: 39215025 Free PMC article.
Translational genomics of nasopharyngeal cancer.
Tsang CM, Lui VWY, Bruce JP, Pugh TJ, Lo KW. Tsang CM, et al. Among authors: bruce jp. Semin Cancer Biol. 2020 Apr;61:84-100. doi: 10.1016/j.semcancer.2019.09.006. Epub 2019 Sep 12. Semin Cancer Biol. 2020. PMID: 31521748 Free article. Review.
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.
Cindy Yang SY, Lien SC, Wang BX, Clouthier DL, Hanna Y, Cirlan I, Zhu K, Bruce JP, El Ghamrasni S, Iafolla MAJ, Oliva M, Hansen AR, Spreafico A, Bedard PL, Lheureux S, Razak A, Speers V, Berman HK, Aleshin A, Haibe-Kains B, Brooks DG, McGaha TL, Butler MO, Bratman SV, Ohashi PS, Siu LL, Pugh TJ. Cindy Yang SY, et al. Among authors: bruce jp. Nat Commun. 2021 Aug 26;12(1):5137. doi: 10.1038/s41467-021-25432-7. Nat Commun. 2021. PMID: 34446728 Free PMC article. Clinical Trial.
Nasopharyngeal Cancer: Molecular Landscape.
Bruce JP, Yip K, Bratman SV, Ito E, Liu FF. Bruce JP, et al. J Clin Oncol. 2015 Oct 10;33(29):3346-55. doi: 10.1200/JCO.2015.60.7846. Epub 2015 Sep 8. J Clin Oncol. 2015. PMID: 26351340 Review.
All is not lost: learning from 9p21 loss in cancer.
Spiliopoulou P, Yang SYC, Bruce JP, Wang BX, Berman HK, Pugh TJ, Siu LL. Spiliopoulou P, et al. Among authors: bruce jp. Trends Immunol. 2022 May;43(5):379-390. doi: 10.1016/j.it.2022.03.003. Epub 2022 Apr 1. Trends Immunol. 2022. PMID: 35379580 Free article. Review.
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer.
Hernando-Calvo A, Han M, Ayodele O, Wang BX, Bruce JP, Abbas-Aghababazadeh F, Vila-Casadesús M, Sanz-Garcia E, Yang SYC, Berman HK, Vivancos A, Lam B, Lungu I, Salawu A, Stayner LA, Haibe-Kains B, Bedard PL, Avery L, Razak ARA, Pugh TJ, Spreafico A, Siu LL, Hansen AR. Hernando-Calvo A, et al. Among authors: bruce jp. Clin Colorectal Cancer. 2024 Sep;23(3):272-284.e9. doi: 10.1016/j.clcc.2024.05.002. Epub 2024 May 15. Clin Colorectal Cancer. 2024. PMID: 38960798 Free article. Clinical Trial.
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.
Lheureux S, Prokopec SD, Oldfield LE, Gonzalez-Ochoa E, Bruce JP, Wong D, Danesh A, Torti D, Torchia J, Fortuna A, Singh S, Irving M, Marsh K, Lam B, Speers V, Yosifova A, Oaknin A, Madariaga A, Dhani NC, Bowering V, Oza AM, Pugh TJ. Lheureux S, et al. Among authors: bruce jp. Clin Cancer Res. 2023 Sep 15;29(18):3706-3716. doi: 10.1158/1078-0432.CCR-23-0797. Clin Cancer Res. 2023. PMID: 37327320 Free PMC article. Clinical Trial.
56 results